StockNews.AI

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

StockNews.AI • 7 hours

IUIIVF
High Materiality8/10

Information

Partnership enables broader adoption of FemaSeed through a trusted community health provider serving...

Original source

AI Summary

Femasys partners with Refuah Health Center to enhance FemaSeed adoption. The partnership aims to improve community-based fertility care access. FemaSeed shows double pregnancy rates compared to IUI in clinical trials. FemBloc received regulatory approval in key markets, enhancing product portfolio. Femasys focuses on patient-centered fertility treatment options.

Sentiment Rationale

The partnership expands Femasys' market reach and FemaSeed's adoption, likely driving revenue growth. Historical partnerships in biotech often correlate with stock price increases due to enhanced product visibility.

Trading Thesis

Increasing access to FemaSeed can lead to steady revenue growth over time as adoption expands. Long-term market penetration and the potential for additional partnerships may significantly enhance Femasys' valuations.

Market-Moving

  • Femasys partners with Refuah Health Center to enhance FemaSeed adoption.
  • The partnership aims to improve community-based fertility care access.
  • FemaSeed shows double pregnancy rates compared to IUI in clinical trials.

Key Facts

  • Femasys partners with Refuah Health Center to enhance FemaSeed adoption.
  • The partnership aims to improve community-based fertility care access.
  • FemaSeed shows double pregnancy rates compared to IUI in clinical trials.
  • FemBloc received regulatory approval in key markets, enhancing product portfolio.
  • Femasys focuses on patient-centered fertility treatment options.

Companies Mentioned

  • IUI (IUI)
  • IVF (IVF)

Corporate Developments

The partnership directly influences Femasys' growth strategy, enhancing commercial availability and market access.

Femasys Partners with Refuah Health Center to Enhance Fertility Treatment Access

ATLANTA, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a prominent biomedical innovator focused on enhancing accessibility and affordability in fertility and non-surgical permanent birth control solutions, has announced a new partnership with Refuah Health Center. This collaboration aims to introduce FemaSeed as a first-line approach in infertility treatment, significantly expanding patient access and utilization in community-based fertility care.

Expanding Commercial Footprint in Fertility Care

The partnership between Femasys and Refuah Health Center is poised to strengthen Femasys' position in the field of community-based fertility care. FemaSeed will serve as a vital entry point for individuals seeking infertility solutions, making the IVF journey more accessible and less complex.

Kathy Lee-Sepsick, CEO of Femasys, remarked, “This partnership is an important step forward in expanding the commercial availability of FemaSeed within community-based fertility care. With Refuah’s trusted care model and strong patient engagement, we expect to accelerate adoption of FemaSeed by providing a more accessible, cost-effective, and patient-centered starting point for fertility treatment.”

Innovative Approach to Fertility Treatment with FemaSeed

FemaSeed® is a next-generation artificial insemination solution that precisely delivers sperm to the fallopian tube, improving fertilization outcomes. As a first-line treatment, it presents a **safe**, **effective**, and **cost-effective** alternative to traditional intrauterine insemination (IUI). In clinical trials, FemaSeed demonstrated over **double the pregnancy rates** than IUI in cases with low male sperm count (NCT0468847).

  • Authorized for use in the U.S., Europe, UK, Canada, and Israel.
  • Proven to be less invasive and lower-risk compared to IVF.
  • Designed to help patients start their fertility journey sooner.

Dr. Angela Silber, M.D., OB/GYN at Refuah Health Center, stated, “FemaSeed offers an accessible, patient-centered approach that may help many individuals begin care sooner and with less complexity, and we are pleased to make it available as an early step in treatment.”

About Femasys and its Product Portfolio

Femasys is dedicated to making fertility solutions and non-surgical permanent birth control more accessible and cost-effective for women worldwide. The company has developed a robust portfolio of innovative therapeutic and diagnostic products, including:

  • FemaSeed: A first-step treatment for infertility.
  • FemVue: A companion diagnostic for assessing fallopian tube function.
  • FemBloc: A non-surgical option for permanent birth control, approved in several international markets.

Published clinical data indicates that FemaSeed is twice as effective as standard IUI, with a similar safety profile and high satisfaction rates among patients and practitioners.

Refuah Health Center: Commitment to Community Care

Refuah Health Center, established in 1992, serves as a Federally Qualified Community Health Center (FQHC) that provides affordable and comprehensive medical, dental, and behavioral health services. Its mission is to eliminate barriers to healthcare and ensure that high-quality care is accessible to all, regardless of economic status.

Forward-Looking Statements

This announcement contains forward-looking statements involving risks and uncertainties. Actual results may differ materially from expectations due to various factors, including regulatory approvals and market conditions. Femasys is committed to transparency and will provide updates as necessary.

Related News